



Narhex Life Sciences Ltd

Level 24, 44 St George's Terrace
PERTH WA 6000
P: +61-8-6211 5099
F: +61-8-9218 8875

ABN: 51 094 468 318

17 December 2014

Company Announcements Office
Australian Securities Exchange
10th Floor
20 Bond Street
SYDNEY, NSW 2000.

Dear Sir

COMPLETION OF PLACEMENT

The Directors of Narhex Life Sciences Limited ("**Narhex**" or the "**Company**") refer to the Company's announcement dated 2 October 2014 in relation to the binding Heads of Agreement ("**Agreement**") to acquire 100% of ResApp Diagnostics Pty Ltd, an Australian based medical device company. The Company advises that the amount to be raised under the proposed capital raising has been varied, with a total of \$900,000 to be raised in two tranches.

The Company is pleased to advise it has completed tranche 1 of the capital raising issuing 110,000,000 Shares at \$0.005 to raise \$550,000. Sophisticated investors who participated in the placement were also entitled to be issued one free attaching option for every 2 shares subscribed for. The free attaching options are exercisable at \$0.01 and have an expiry date of 31 December 2016, as approved by Shareholders at the Company's Annual General Meeting held on 26 November 2014.

ASX has advised that 10,000,000 Shares issued under tranche 1 of the capital raising will be treated as seed capital and will not be quoted with ASX escrow restrictions to be applied.

Funds raised will be used for working capital and the costs associated with re-compliance with Chapters 1 & 2 of the ASX Listing Rules.

Yours faithfully

Nicki Farley
Company Secretary